Qube Research & Technologies (QRT)
CADL icon

Qube Research & Technologies (QRT)’s Candel Therapeutics CADL Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$2 – 3860
2024
Q1 		$2 Hold
1
– – ﹤0.01% 4364
2023
Q4 		$1 Hold
1
– – ﹤0.01% 4269
2023
Q3 		$1 Buy
+1
New +$1 ﹤0.01% 4033

Other funds holding CADL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
MML Investors Services
MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CADL Position: Q2 2024 in Review

Qube Research & Technologies (QRT) sold out of Candel Therapeutics (CADL) in Q2 2024, closing a stake of 1 share — an estimated $2 sold.

Qube Research & Technologies (QRT) first reported a position in CADL in Q3 2023 and held it in 3 quarters. The position peaked at $2 in Q1 2024. 45 funds tracked by Wall St. Rank hold CADL as of Q2 2024.

  • Qube Research & Technologies (QRT) reported no remaining Candel Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 1 Candel Therapeutics share in Q2 2024, an estimated $2.
  • Qube Research & Technologies (QRT) first reported a position in Candel Therapeutics in Q3 2023 and held it in 3 quarters.
  • Qube Research & Technologies (QRT)'s Candel Therapeutics position peaked at $2 in Q1 2024.
  • 45 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2024, filed 14 Aug 2024.